Phosphodiesterase inhibitors and lung diseases-Reference-Cited by-同舟云学术

Phosphodiesterase inhibitors and lung diseases

Published:2023 Issue: Volume: Page:55-81
ISSN:1054-3589
Container-title:Advances in Pharmacology
language:
Short-container-title:

Author:

Stolfa Ivana,Page Clive

Publisher

Elsevier

Reference118 articles.

1. Dual PDE3/4 and PDE4 inhibitors: Novel treatments for COPD and other inflammatory airway diseases;Abbott-Banner;Basic and Clinical Pharmacology and Toxicology,2014

2. Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases;Armani;Journal of Medicinal Chemistry,2014

3. Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: Inhibition and beyond;Baillie;Nature Reviews. Drug Discovery,2019

4. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma;Banner;European Respiratory Journal,1995

5. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers;Barber;American Journal of,2004

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological profile of dicaffeoylquinic acids and their role in the treatment of respiratory diseases;Frontiers in Pharmacology;2024-08-22

2. Inhalational Drug Devices: Revisiting the Linchpin of Asthma Management;Journal of Personalized Medicine;2024-08-16

3. Nonsurgical therapy for lumbar spinal stenosis caused by ligamentum flavum hypertrophy: A review;Medicine;2024-07-05

4. cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment;Journal of Hematology & Oncology;2024-01-17